Allogene Therapeutics Inc

NASDAQ:ALLOUnited States

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.

Contact Information

Headquarters

210 East Grand AvenueSOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-457-2700

Fax

302-636-5454

Executives

Executive Chairman of the Board

Arie Belldegrun

President, Chief Executive Officer, Co-Founder, Director

David Chang

Chief Financial Officer, Executive Vice President

Geoffrey Parker

Executive Vice President, Chief Technical Officer

Timothy Moore

Executive Vice President - Research and Development, Chief Medical Officer

Zachary Roberts